Clinical Trials Browser

Recruiting × Interventional × sargramostim × Clear all

NCT04237623 2026-04-16

GM-CSF With Post-Transplant Cyclophosphamide

Phase 2 Recruiting

Transplant-Related Hematologic Malignancy

NCT07078604 2026-04-07

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT05544968 2026-04-03

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Neoplasms, Recurrence, Lymphoma, Large-Cell, Anaplastic

NCT06450041 2026-03-23

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Phase 2 Recruiting

Neuroblastoma

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06202066 2026-03-11

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Phase 2 Recruiting

Adenoma, Islet Cell

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3 Recruiting

Neuroblastoma, Ganglioneuroblastoma

NCT06528496 2026-02-10

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Phase 2 Recruiting

Neuroblastoma

NCT06626516 2025-11-28

Tebentafusp-tebn With LDT in Metastatic UM

Phase 1/2 Recruiting

Uveal Melanoma, Melanoma

NCT07027748 2025-07-14

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Phase 1 Recruiting

Neuroblastoma

NCT04211675 2025-05-13

STING

Phase 1/2 Recruiting

Neuroblastoma

NCT05771584 2024-07-10

Conerstone3

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05101356 2024-05-21

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

Phase 1/2 Recruiting

Adenocarcinoma, Neoplasm Metastasis

NCT05344209 2023-11-09

LUNGVAC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms